Patents by Inventor John Michael Gansner

John Michael Gansner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES
    Publication number: 20250283071
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: October 28, 2021
    Publication date: September 11, 2025
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Mark K. SCHLEGEL, Adam CASTORENO, Christopher BROWN, Lucas D. BONDURANT, Anna BORODOVSKY, William CANTLEY, Elena CASTELLANOS-RIZALDOS, Aimee M. DEATON, Jonathan Edward FARLEY, Elane FISHILEVICH, John Michael GANSNER, Jason GILBERT, Vasant R. JADHAV, Charalambos KAITTANIS, Mark KEATING, Jingxuan LIU, James MCININCH, Stuart MILSTEIN, Bhaumik A. PANDYA, Mangala Meenakshi SOUNDARAPANDIAN, Jeffrey ZUBER
  • TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240182905
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermiedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.
    Type: Application
    Filed: November 1, 2023
    Publication date: June 6, 2024
    Inventors: Aimee M. Deaton, John Michael Gansner, James D. McIninch, Mark K. Schlegel, Benjamin P. Garfinkel
  • Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof
    Patent number: 11866710
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: January 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Aimee M. Deaton, John Michael Gansner, James D. McIninch, Mark K. Schlegel, Benjamin P. Garfinkel
  • METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION
    Publication number: 20230407312
    Abstract: The invention relates methods of using RNAi agents to inhibit expression of HAO1 and methods of treating subjects having primary hyperoxaluria, e.g., PH1.
    Type: Application
    Filed: May 26, 2023
    Publication date: December 21, 2023
    Inventors: Tracy L. McGregor, John Michael Gansner, Ishir Bhan
  • TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230220396
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Transmembrane protease, serine 6 (TMPRSS6) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS6 gene and to methods of preventing and treating a TMPRSS6-associated disorder, e.g., a disorder associated with iron overload and/or a disorder of ineffective erythropoiesis, e.g., hereditary hemochromatosis, ?-thalassemia (e.g., ?-thalassemia major and ?-thalassemia intermiedia), polycythemia vera, myelodysplastic syndrome, congenital dyserythropoietic anemias, pyruvate kinase deficiency, erythropoietic porphyria, Parkinson's Disease, Alzheimer's Disease or Friedreich's Ataxia.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Aimee M. Deaton, John Michael Gansner, James D. McIninch, Mark K. Schlegel, Benjamin P. Garfinkel